Biopharma · FDA Approvals · Stock
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer th…
Assets on file: envudeucitinib
Dated catalysts for ALMS, including recently decided ones.
Every first-hand event for ALMS, newest first.
Alumis: ONWARD3 shows 54% PASI 100 at 48 weeks for envudeucitinib
The ONWARD3 long-term extension data demonstrate that 54% of patients achieved complete skin clearance (PASI 100) and 75% achieved PASI 90 after up to 48 weeks of continuous treatment, reinforcing the Phase 3 topline results and supporting the planned NDA submission in Q4 2026.
Companies in the same sector closest to ALMS in market value.